Home
Platform
About
Pipeline
News
Careers
More
January 6, 2023
Today's announcement marks the first TriNKET opt-in outside of oncology. Dragonfly to receive a $25 million payment and is eligible to...
November 1, 2022
Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial Dragonfly Therapeutics, Inc....
March 31, 2022
Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs. Hesham Aboshady MD,...
November 24, 2021
The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly...
November 23, 2021
Merck executes option to license its second immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets....
January 12, 2021
Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.
December 2, 2020
The U.S. Big Pharma is getting its hands on its first TriNKET immunotherapy candidate from the biotech, which comes after the pair...
August 18, 2020
Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy...
August 17, 2020
By Ben Adams Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’...
July 7, 2020
Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add...
March 19, 2020
Biotech CEO Bill Haney says 'you focus on the things that make a difference' Fidelity Management and Research has led a new round for...
November 12, 2019
Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2...
December 8, 2022
Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2. In its Phase 1 study DF1001 was...
May 2, 2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of...
March 1, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk,...
Merck & Co. Inc. has decided to move forward on its option to license a second drug from Waltham-based Dragonfly Therapeutics. The two...
November 9, 2021
The company announces that its lead TriNKET™ immunotherapy program DF1001, a HER2-targeted NK cell engager therapy...
Dragonfly’s partnership with AbbVie is beginning to bear fruit.
December 1, 2020
A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for each drug...
Dive Brief: Bristol Myers Squibb has licensed from privately held biotech Dragonfly Therapeutics an experimental immunotherapy that it...
For Dragonfly’s IL-12 Investigational Immunotherapy Program Agreement Includes DF6002, With Potential to Advance Treatment of Solid...
July 6, 2020
As the latest Bristol Myers pact spurs expansion plans -- outside the US Bristol Myers Squibb is making a habit out of collaborating with...
November 20, 2019
Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly...
October 2, 2018
More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at...
December 6, 2022
In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions...
April 21, 2022
Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in...
This morning, investors in privately-held Dragonfly Therapeutics are thankful after Merck opted to license its second TriNKET...
Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck —...
October 18, 2021
The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical...
December 10, 2020
In the second year of Endpoints News’ budding tradition of highlighting women blazing trails in biopharma R&D, we’ve seen a number of...
November 24, 2020
and also Strengthens Scientific Advisory Board WALTHAM, Mass., Nov. 24, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or...
With a potential IL-12 game-changer This morning Bristol Myers R&D maestro Rupert Vessey is taking the wraps off one of the biggest cash...
August 10, 2020
Published: Aug 10, 2020 WALTHAM, Mass., Aug. 10, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc.. ("Dragonfly" or the "Company"), today...
May 11, 2020
Published: May 11, 2020 Tapan Maniar M.D. with 10+ years of biotech and pharma experience has been appointed head of clinical development...
November 13, 2019
WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel...
with billions on the line A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally...